A risk to mental health or a miracle cure? Confused About Cannabis? Here’s What No One Tells You
Cannabis, known for its medicinal properties, is utilized in certain regions of the world to alleviate pain and serve as an antidepressant. Furthermore, researchers are exploring the potential of a specific component found in cannabis for treating psychosis.
A recent research study conducted by the University of Oslo and published in the Lancet Psychiatry has shed light on a significant finding: a shared genetic foundation for both cannabis use and psychiatric disorders, including schizophrenia and bipolar disorder.
These groundbreaking results suggest that there may be a specific segment of the population that carries a higher genetic predisposition for both cannabis use and psychiatric disorders.
The relationship between cannabis use and psychiatric disorders has long been a topic of debate. Cannabis is a psychoactive substance known to occasionally induce symptoms similar to psychosis. Furthermore, individuals diagnosed with psychiatric disorders associated with psychosis, such as schizophrenia and bipolar disorder, have been found to have a higher prevalence of cannabis use.
The study emphasizes the crucial role of genetic factors in determining an individual’s vulnerability to developing psychiatric disorders, as well as their inclination to use cannabis. Interestingly, certain genetic variations associated with cannabis use have also been linked to psychiatric disorders.
According to the recent study conducted by Drs. Weiqiu Cheng and Nadine Parker, there is compelling evidence suggesting a shared genetic basis for this association.
The results of the study reveals, “there is a shared genetic basis underlying our susceptibility to both cannabis use and certain psychiatric disorders,” comments lead author Weiqiu Cheng.
According to their findings, “a subset of the population is at high risk for both cannabis use and psychiatric disorders, based on their genetic propensity.”
Utilizing sophisticated statistical modeling techniques, the study demonstrates that a significant portion of shared genetic variants raises the likelihood of both cannabis use and the development of either schizophrenia or bipolar disorder. However, there exist certain genetic variants that exhibit contradictory effects, heightening the risk of cannabis use while diminishing the risk of these two psychiatric disorders. This suggests a multifaceted and intricate relationship between these factors.
“These findings are important as they show that the complex links between cannabis use and these disorders may not only be caused by cannabis use itself, but could also be driven by shared genetic susceptibility,” points out researcher Nadine Parker.
Cannabis, known for its medicinal properties, is utilized in certain regions of the world to alleviate pain and serve as an antidepressant. Furthermore, researchers are exploring the potential of a specific component found in cannabis for treating psychosis.
“Shared genetic variants with opposing effects may suggest the presence of biological mechanisms that could support the beneficial effects of cannabis,” remarks the team.
The recent discoveries have significant implications for clinical practice. Firstly, these findings hold the potential to shape personalized healthcare by enabling preventive and interventional measures for individuals at high risk. This could involve measures such as reducing cannabis usage in those with a genetic predisposition to schizophrenia and bipolar disorder. Secondly, further research into the biological effects of these shared genetic variants may contribute to the development of more precise treatment approaches. Lastly, the enhanced understanding of genetic overlap can assist in stratifying patients for more tailored and specialized treatment strategies.
Image Credit: Getty